Raised B-type natriuretic peptide predicts implantable cardioverter-defibrillator therapy in patients with ischaemic cardiomyopathy

Biomarkers in heart failure: a clinical review

“…Studies have demonstrated a relationship between BNP/NT-proBNP and future sudden death and as an independent predictor of tachyarrhythmia [59,60]. Similarly, elevated B-type naturetic peptides may predict response to CRT [61][62][63].…”

Increased N-terminal-pro-B-type natriuretic peptide levels in patients with appropriate implantable defibrillator therapies

“…These data are consistent with recently published studies in which preimplantation natriuretic peptides levels were found to be a predictor of appropriate defibrillator therapies during the follow-up. [12][13][14] In our study population, a significant number of appropriate interventions were ATP therapies, and these patients may have received device therapies for less severe ventricular tachyarrhythmias. 21,22 Regardless of the type of appropriate therapy, the elevation of NT-ProBNP serum levels suggests the presence of some degree of myocardial derangement.…”

“…Several clinical and electrophysiologic variables have been demonstrated to predict appropriate implantable cardioverter defibrillator (ICD) therapies, including low left ventricular ejection fraction (LVEF), advanced New York Heart Association (NYHA) heart failure class, persistent inducibility of ventricular tachyarrhythmias in the electrophysiology laboratory, lack of beta-blocker therapy, and preimplantation elevated BNP and NT-ProBNP levels. [9][10][11][12][13][14] Given the current expanding indication of implantable defibrillators and heart failure devices with defibrillation systems, the ability to recognize further predictors of the occurrence of appropriate device therapies may allow physicians to identify patients who benefit most and to implement preventive measures to avoid discomfort and anxiety from device shocks.…”

Risk Stratification of Sudden Cardiac Death After Acute Myocardial Infarction

“…112 In a small study in which NT-proBNP was assessed prior to ICD implantation in patients with MI and LVEF ≤ 30%, a NT-proBNP level > 2,536 pg/ml was independently associated with appropriate ICD therapies for ventricular arrhythmias over one year of follow-up [RR: 7.7; (p = 0.024)], even after adjustment for LVEF, NYHA functional class, and multiple other covariates. 113 In another retrospective study evaluating the associations between BNP, ventricular arrhythmias, and total mortality in ICD recipients, elevated BNP and NT-proBNP levels were independently associated with appropriate ICD therapies for ventricular arrhythmias, and the risk of arrhythmia significantly exceeded the risk for total mortality. 114 Multiple other studies have linked elevated BNP levels post-MI to other adverse cardiovascular factors, such as total mortality and clinical heart failure.…”